Aktis Oncology, Inc. Common stock (AKTS)vsRevolution Medicines Inc (RVMD)
AKTS
Aktis Oncology, Inc. Common stock
$18.87
-5.13%
HEALTHCARE · Cap: $1.12B
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Aktis Oncology, Inc. Common stock generates 1015% more annual revenue ($8.28M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. AKTS earns a higher WallStSmart Score of 35/100 (F).
AKTS
Hold35
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 123.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AKTS
The strongest argument for AKTS centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 123.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : AKTS
The primary concerns for AKTS are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
AKTS profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
AKTS is growing revenue faster at 123.0% — sustainability is the question.
AKTS generates stronger free cash flow (-26M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AKTS scores higher overall (35/100 vs 24/100) and 123.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aktis Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?